AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Phthalylsulfathiazole is effective against a range of bacterial infections, particularly those caused by susceptible strains of enteric bacteria. It is commonly used to treat infections of the gastrointestinal tract, such as bacterial diarrhea and enteritis.
Antidiarrheal: Phthalylsulfathiazole is often used as an antidiarrheal medication to reduce the frequency and severity of diarrhea associated with bacterial infections. By inhibiting the growth of bacteria in the intestines, it helps to alleviate symptoms and promote recovery.
Gastrointestinal Infections: It is indicated for the treatment of various gastrointestinal infections, including acute bacterial gastroenteritis, traveler's diarrhea, and enteric fever caused by susceptible organisms.
Mechanism of Action: Phthalylsulfathiazole works by inhibiting the growth and multiplication of bacteria in the gastrointestinal tract. It interferes with the synthesis of bacterial folate, which is essential for the production of DNA and proteins in bacteria, thereby preventing their growth and replication.
Side Effects: Common side effects of phthalylsulfathiazole may include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea. Allergic reactions, including skin rashes and itching, may occur in some individuals. In rare cases, severe allergic reactions such as anaphylaxis may occur.
Drug Interactions: Phthalylsulfathiazole may interact with other medications, particularly those that affect the absorption or metabolism of the drug. It is important to consult with a healthcare professional before taking phthalylsulfathiazole concurrently with other medications.
Dosage and Administration: Phthalylsulfathiazole is typically administered orally in the form of tablets or suspension. The dosage and duration of treatment depend on the severity of the infection and the individual's age, weight, and medical history. It is important to follow the prescribed dosage and complete the full course of treatment as directed by a healthcare provider.
Resistance: As with other antibiotics, the overuse or misuse of phthalylsulfathiazole can lead to the development of bacterial resistance, making future infections more difficult to treat. Therefore, it is important to use phthalylsulfathiazole judiciously and only when necessary.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0 | 0 | |
| ADHD | 0.2 | 0.4 | -1 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.8 | 0.8 | |
| Allergies | 1 | 0.3 | 2.33 |
| Allergy to milk products | 0.7 | 0.3 | 1.33 |
| Alzheimer's disease | 0.7 | 0.9 | -0.29 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.5 | 0 |
| Ankylosing spondylitis | 0.9 | 0.4 | 1.25 |
| Anorexia Nervosa | 0.1 | 0.3 | -2 |
| Antiphospholipid syndrome (APS) | 0.8 | 0 | 0 |
| Asthma | 1 | 0.3 | 2.33 |
| Atherosclerosis | 0.1 | 0.5 | -4 |
| Atrial fibrillation | 0.4 | 0.4 | 0 |
| Autism | 3 | 1.2 | 1.5 |
| Barrett esophagus cancer | 0.1 | 0.2 | -1 |
| benign prostatic hyperplasia | 0.2 | 0.2 | |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 0.4 | 0.5 | -0.25 |
| Brain Trauma | 0.1 | -0.1 | |
| Cancer (General) | 0.8 | -0.8 | |
| Carcinoma | 1 | 0.1 | 9 |
| Celiac Disease | 0.7 | 0.2 | 2.5 |
| Cerebral Palsy | 0.5 | 0.1 | 4 |
| Chronic Fatigue Syndrome | 2.8 | 0.5 | 4.6 |
| Chronic Kidney Disease | 1.4 | 0.1 | 13 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.1 | 7 |
| Chronic Urticaria (Hives) | 1.1 | 0.2 | 4.5 |
| Coagulation / Micro clot triggering bacteria | 1 | 0.3 | 2.33 |
| Colorectal Cancer | 1.1 | 1.1 | |
| Constipation | 0.2 | 0.1 | 1 |
| Coronary artery disease | 0.3 | 0.3 | |
| COVID-19 | 3 | 1.2 | 1.5 |
| Crohn's Disease | 2.1 | 0.4 | 4.25 |
| cystic fibrosis | 0.6 | 0.1 | 5 |
| deep vein thrombosis | 0.6 | 0.3 | 1 |
| Depression | 3.5 | 1.5 | 1.33 |
| Dermatomyositis | 0.2 | 0.2 | |
| Eczema | 0.5 | 0.6 | -0.2 |
| Endometriosis | 1 | 1 | |
| Eosinophilic Esophagitis | 0.1 | 0.1 | |
| Epilepsy | 0.7 | 0.5 | 0.4 |
| Fibromyalgia | 0.8 | 0.3 | 1.67 |
| Functional constipation / chronic idiopathic constipation | 1.2 | 0.8 | 0.5 |
| gallstone disease (gsd) | 0.5 | 0.1 | 4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | 0 |
| Generalized anxiety disorder | 1 | 0.3 | 2.33 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.2 | -0.2 | |
| Graves' disease | 0.1 | 0.1 | 0 |
| Halitosis | 0.1 | 0.2 | -1 |
| Hashimoto's thyroiditis | 0.5 | 0.1 | 4 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 1.2 | 1.2 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.1 | 1 |
| hyperglycemia | 0.2 | 0.3 | -0.5 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypersomnia | 0 | 0 | |
| hypertension (High Blood Pressure | 0.6 | 0.6 | 0 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 0.5 | -0.5 | |
| Inflammatory Bowel Disease | 1.9 | 0.7 | 1.71 |
| Insomnia | 0.3 | 0.1 | 2 |
| Intelligence | 0.2 | 0.2 | |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 1.1 | 0.3 | 2.67 |
| Liver Cirrhosis | 1 | 0.7 | 0.43 |
| Long COVID | 1.6 | 0.3 | 4.33 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.2 | 0.1 | 1 |
| Mast Cell Issues / mastitis | 0.5 | 0.5 | |
| ME/CFS with IBS | 0.5 | 0 | 0 |
| ME/CFS without IBS | 2.1 | 0 | 0 |
| Metabolic Syndrome | 2.3 | 1 | 1.3 |
| Mood Disorders | 4.1 | 1.9 | 1.16 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 2.3 | 1.2 | 0.92 |
| Multiple system atrophy (MSA) | 0.6 | 0.6 | |
| neuropathic pain | 0.1 | -0.1 | |
| Neuropathy (all types) | 0.3 | 0.2 | 0.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.7 | 0.1 | 6 |
| NonCeliac Gluten Sensitivity | 0.5 | 0 | 0 |
| Obesity | 1.6 | 0.7 | 1.29 |
| obsessive-compulsive disorder | 1.1 | 0.7 | 0.57 |
| Osteoarthritis | 1.2 | 1.2 | |
| Osteoporosis | 0.9 | 0.1 | 8 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 2.1 | 1.3 | 0.62 |
| Polycystic ovary syndrome | 0.6 | 0.3 | 1 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.1 | -0.1 | |
| Psoriasis | 1.1 | 0.3 | 2.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 0.5 | 2 |
| Rosacea | 0.3 | 0.3 | 0 |
| Schizophrenia | 1.3 | 0.3 | 3.33 |
| scoliosis | 0 | 0 | |
| Sjögren syndrome | 0.5 | 0.1 | 4 |
| Sleep Apnea | 0.1 | 0.5 | -4 |
| Slow gastric motility / Gastroparesis | 0.5 | 0.5 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | |
| Stress / posttraumatic stress disorder | 0.9 | 1 | -0.11 |
| Systemic Lupus Erythematosus | 1.5 | 0.1 | 14 |
| Tourette syndrome | 0 | 0 | 0 |
| Type 1 Diabetes | 0.4 | 0.5 | -0.25 |
| Type 2 Diabetes | 2 | 1.4 | 0.43 |
| Ulcerative colitis | 1.3 | 0.6 | 1.17 |
| Unhealthy Ageing | 1.6 | 0.1 | 15 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [44.222.131 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.131 ]
